Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
29 Sep 2023
Historique:
received: 08 03 2023
accepted: 25 08 2023
medline: 29 9 2023
pubmed: 29 9 2023
entrez: 29 9 2023
Statut: epublish

Résumé

Respiratory syncytial virus (RSV) causes a high disease burden in older adults. An effective vaccine for this RSV-primed population may need to boost/elicit robust RSV-neutralizing antibody responses and recall/induce RSV-specific T cell responses. To inform the selection of the vaccine formulation for older adults, RSVPreF3 (RSV fusion glycoprotein engineered to maintain the prefusion conformation) with/without AS01 adjuvant was evaluated in mice and bovine RSV infection-primed cattle. In mice, RSVPreF3/AS01 elicited robust RSV-A/B-specific neutralization titers and RSV F-specific polyfunctional CD4

Identifiants

pubmed: 37773185
doi: 10.1038/s41541-023-00729-4
pii: 10.1038/s41541-023-00729-4
pmc: PMC10541443
doi:

Types de publication

Journal Article

Langues

eng

Pagination

143

Informations de copyright

© 2023. Springer Nature Limited.

Références

Vaccine. 2012 Apr 26;30(20):3126-35
pubmed: 22326899
Am J Trop Med Hyg. 2015 Apr;92(4):698-708
pubmed: 25646261
PLoS One. 2017 Oct 26;12(10):e0186854
pubmed: 29073183
NPJ Vaccines. 2021 May 21;6(1):78
pubmed: 34021167
Lancet Infect Dis. 2023 Jan;23(1):e2-e21
pubmed: 35952703
Sci Transl Med. 2020 Jul 22;12(553):
pubmed: 32718991
Science. 2013 May 31;340(6136):1113-7
pubmed: 23618766
Hum Vaccin Immunother. 2016 Aug 2;12(8):2092-2095
pubmed: 26933767
Vaccines (Basel). 2021 Jan 20;9(2):
pubmed: 33498370
Vaccine. 2013 Apr 18;31 Suppl 2:B209-15
pubmed: 23598484
Elife. 2020 Apr 29;9:
pubmed: 32342859
Clin Immunol. 2016 Aug;169:16-27
pubmed: 27236001
NPJ Vaccines. 2023 Mar 8;8(1):34
pubmed: 36890168
Clin Infect Dis. 2019 Jul 2;69(2):197-203
pubmed: 30452608
Semin Immunol. 2018 Oct;39:14-21
pubmed: 29801750
J Infect Dis. 2023 Mar 28;227(6):761-772
pubmed: 35904987
Pathogens. 2019 May 21;8(2):
pubmed: 31117229
Mech Ageing Dev. 2006 Jun;127(6):560-6
pubmed: 16516272
Expert Rev Vaccines. 2017 Jan;16(1):55-63
pubmed: 27448771
Sci Transl Med. 2020 Nov 11;12(569):
pubmed: 33177181
BMC Infect Dis. 2015 Oct 23;15:443
pubmed: 26497750
NPJ Vaccines. 2017 Sep 8;2:25
pubmed: 29263880
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24
pubmed: 21586636
Nat Commun. 2015 Dec 21;6:10224
pubmed: 26687547
Clin Vaccine Immunol. 2013 Feb;20(2):239-47
pubmed: 23239796
Vaccine. 2004 Sep 28;22(29-30):3831-40
pubmed: 15364429
Innate Immun. 2008 Aug;14(4):223-31
pubmed: 18669608
Front Immunol. 2017 Aug 14;8:943
pubmed: 28855902
Elife. 2020 Mar 24;9:
pubmed: 32204792
Vaccine. 2017 Jan 11;35(3):469-480
pubmed: 27908639
Influenza Other Respir Viruses. 2023 Jan;17(1):e13031
pubmed: 36369772
Immun Ageing. 2010 Oct 20;7:14
pubmed: 20961416
Science. 2019 Aug 2;365(6452):505-509
pubmed: 31371616
Expert Rev Vaccines. 2019 Sep;18(9):935-950
pubmed: 31446807
J Infect Dis. 2017 Jan 1;215(1):24-33
pubmed: 27694633
Nat Commun. 2017 Oct 20;8(1):1085
pubmed: 29057917
Trends Immunol. 2009 Mar;30(3):124-30
pubmed: 19211304
Lancet Infect Dis. 2018 Oct;18(10):e295-e311
pubmed: 29914800
Viral Immunol. 2018 Jan/Feb;31(1):11-22
pubmed: 28618246
Nat Commun. 2015 Sep 03;6:8143
pubmed: 26333350
Front Bioeng Biotechnol. 2020 Dec 11;8:608050
pubmed: 33363134
Open Forum Infect Dis. 2018 Nov 27;5(12):ofy316
pubmed: 30619907
Blood. 2001 Oct 15;98(8):2498-507
pubmed: 11588048
Vaccine. 2015 Jul 31;33(32):4025-34
pubmed: 26072017
J Immunol. 2014 Aug 15;193(4):1920-30
pubmed: 25024381
J Infect Dis. 2018 Apr 23;217(10):1616-1625
pubmed: 29401325
Cell Rep Med. 2021 Feb 22;2(3):100207
pubmed: 33763653
Sci Transl Med. 2015 Oct 14;7(309):309ra162
pubmed: 26468324
Immunity. 2019 Sep 17;51(3):429-442
pubmed: 31533056
Front Immunol. 2019 Mar 22;10:548
pubmed: 30967872
J Allergy Clin Immunol. 2020 May;145(5):1309-1321
pubmed: 32386655
N Engl J Med. 2023 Feb 16;388(7):595-608
pubmed: 36791160
Curr Opin Immunol. 2019 Aug;59:42-48
pubmed: 31003070
Vaccine. 2018 Oct 29;36(45):6660-6673
pubmed: 30292456
J Infect Dis. 2002 Mar 1;185(5):682-5
pubmed: 11865426
Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485
pubmed: 36299530

Auteurs

Badiaa Bouzya (B)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Ronan Nicolas Rouxel (RN)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.
MSD Animal Health, Thormøhlensgate 55, 5006, Bergen, Norway.

Lionel Sacconnay (L)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Romuald Mascolo (R)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Laurence Nols (L)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Stéphanie Quique (S)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Loïc François (L)

Akkodis, Belgium c/o GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Anne Atas (A)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Lucile Warter (L)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Nancy Dezutter (N)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium.

Clarisse Lorin (C)

GSK, Rue de l'Institut 89, 1330, Rixensart, Belgium. clarisse.m.lorin@gsk.com.

Classifications MeSH